Mersana Therapeutics, Inc. (MRSN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $1.51 per share versus the Zacks Consensus Estimate of a loss of $1.44. This compares to a loss of $2.25 per share a year ago.
Mersana Therapeutics, Inc. (MRSN) M&A Call Transcript
Mersana Therapeutics, Inc. ( MRSN ) M&A Call November 13, 2025 8:00 AM EST Company Participants Joey Perrone - Senior Vice President of Finance & Investor Relations Jeremy Bender - CEO, President & Director Michael Vasconcelles - Head of Research & Development Charles York - COO & CFO Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Andrea Tan - Goldman Sachs Group, Inc., Research Division Alec Stranahan - BofA Securities, Research Division Kelsey Goodwin - Piper Sandler & Co., Research Division Ami Fadia - Needham & Company, LLC, Research Division Presentation Operator Hello, ladies and gentlemen, and welcome to the conference call and live webcast Day One Biopharmaceuticals to acquire Mersana Therapeutics. [Operator Instructions] Please be advised that this conference call is being recorded.
Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript
Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Brian C. DeSchuytner - Senior VP, CFO & COO Jason Fredette - Senior Vice President of Investor Relations & Corporate Communications Martin H.
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $4.08 per share versus the Zacks Consensus Estimate of a loss of $3.75. This compares to a loss of $5 per share a year ago.
Mersana Therapeutics, Inc. (MRSN) Q1 2025 Earnings Call Transcript
Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q1 2025 Earnings Conference Call May 15, 2025 8:00 AM ET Company Participants Jason Fredette - Senior Vice President, Investor Relations & Corporate Communications Marty Huber - President & Chief Executive Officer Brian DeSchuytner - Chief Operating Officer & Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen Charles Zhu - LifeSci Capital Michael Schmidt - Guggenheim Jonathan Chang - Leerink Partners Colleen Kusy - Baird Andy Hsieh - William Blair Karina Rabayeva - Truist Jeet Mukherjee - BTIG Operator Good morning, and welcome to Mersana Therapeutics First Quarter 2025 Conference Call. Currently all participants are in a listen-only mode.
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.16 per share a year ago.
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.16 per share a year ago.
Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?
On Friday, Mersana Therapeutics Inc. MRSN released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin.
Mersana Therapeutics, Inc. (MRSN) Q3 2024 Earnings Call Transcript
Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Jason Fredette - SVP, IR Martin Huber - President & CEO Mohan Bala - SVP, Chief Development Officer Brian DeSchuytner - CFO & COO Conference Call Participants Tara Bancroft - TD Cowen Yen-Der Li - Leerink Partners Charles Zhu - LifeSci Capital Ashiq Mubarack - Citi Yige Guo - Guggenheim Justin Zelin - BTIG Operator Good morning, and welcome to Mersana Therapeutics Third Quarter 2024 Conference Call. Currently all participants are in listen-only mode.
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.35 per share a year ago.
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.47 per share a year ago.
